5-Hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: Can we safely reduce the dose of administered agents?

Cancer

Volumn 104, Issue 1, 2005, Pages 1-18

  Aapro, Matti ^a   Blower, Peter ^b  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b Poole House   (United Kingdom)

Author keywords

5 hydroxytryptamine type 3 receptor antagonist; Antiemetic; Cancer; Dose; Efficacy

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 2D6; DAUNORUBICIN DERIVATIVE; DOLASETRON MESILATE; DOXORUBICIN; ESTRADIOL; FLUOROURACIL; GRANISETRON; HYDROXYDAUNORUBICIN; NICOTINIC RECEPTOR; ONDANSETRON; PALONOSETRON; PREDNISONE; SEROTONIN 3 RECEPTOR; TROPISETRON; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ALCOHOL CONSUMPTION; ANTIEMETIC ACTIVITY; ANXIETY; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; ETHNOLOGY; GENETIC POLYMORPHISM; HUMAN; LOW DRUG DOSE; LUNG CANCER; MOTION SICKNESS; PATIENT COMPLIANCE; PLASMA HALF LIFE; PRIORITY JOURNAL; RADIATION INDUCED EMESIS; RECEPTOR BLOCKING; REVIEW; RISK FACTOR; SEX DIFFERENCE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 20544448255     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21141     Document Type: Review

References (92)

1. Martin CG, Rubenstein EB, Elting LS, Kim YI, Osoba D. Measuring chemotherapy-induced nausea and emesis. Cancer. 2003;98:645-655.
2. Multinational Association of Supportive Care in Cancer (MASCC) Antiemetic Guideline Committee. Antiemetic guidelines from the consensus conference on antiemetic therapy. Perugia International Cancer Conference VII, March 29-31, 2004, Perugia, Italy. Available at: http://www. mascc.org [accessed May 2005].
3. Martin M. The severity and pattern of emesis following different cytotoxic agents Oncology. 1996;53(Suppl 1):26-31.
4. Morrow GR, Roscoe JA, Hickok JT, et al. Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Huntington). 1998;12(3 Suppl 4): 32-37.
5. Gralla R J, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971-2994.
6. ASHP. American Society for Health-System Pharmacists therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm. 1999;56:729-764.
7. Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer. 2002;10:519-522.
8. Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs. 1983;25(Suppl 1):1-7.
9. Coates A, Abraham S, Kaye SB, et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19:203-208.
10. Griffin AM, Butow PN, Coates AS, et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996;7:189-195.
11. 3 antagonists. Br J Cancer. 1997;76:1055-1061.
12. Grunberg SM, Srivastava A, Grunberg KJ, Weeks J. Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score. Support Care Cancer. 2002;10:624-629.
13. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100:2261-2268.
14. Aventis Pharmaceuticals Inc. Anzemet® (dolasetron mesylate) [prescribing information]. Kansas City: Avenus Pharmaceuticals Inc., 2003.
15. Novartis Pharmaceuticals Australia Pty Ltd. Navoban® (tropisetron) [prescribing information]. North Ryde: Novartis Pharmaceuticals Australia Pty Ltd., 1997.
16. MGI Pharma, Inc. Aloxi™ (palonosetron hydrochloride) prescribing information. Bloomington: MGI Pharma, Inc., 2003.
17. 3 receptor antagonists (setrons) for chemotherapy-induced emesis. Economic implications. Pharmacoeconomics. 2000;18:533-556.
18. 3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration. Support Care Cancer. 1998;6:237-243.
19. 3 receptor antagonists. Cancer Today. 2002;Suppl 1:1-15.
20. Doherty KM. Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs. 1999;3:113-119.
21. Xu LH, Koch KL, Summy-Long J, et al. Hypothalamic and gastric myoelectrical responses during vection-induced nausea in healthy Chinese subjects. Am J Physiol. 1993;265: E578-E584.
22. Koffman J, Higginson IJ, Donaldson N. Symptom severity in advanced cancer, assessed in two ethnic groups by interviews with bereaved family members and friends. J R Soc Med. 2003;96:10-16.
23. Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 2003;8:187-198.
24. Kris MG, Gralla RJ, Clark RA, Tyson LB. Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst. 1989;81:42-46.
25. 3 receptors. J Neurochem. 1995;65:104-110.
26. 3 receptors: focus on alcohols and anaesthetic agents. TIPS. 1996;17:95-99.
27. Bentley KR, Barnes NM. 5-hydroxytryptamine3 (5-HT3) receptor-mediated depolarisation of the rat isolated vagus nerve: modulation by trichloroethanol and related alcohols. Eur J Pharmacol. 1998;354:25-31.
28. Sigsgaard T, Herrstedt J, Andersen LJ, et al. Granisetron compared with prednisolone plus metopimazine as antiemetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer. 1999;80:412-418.
29. Soukop M, McQuade B, Hunter E, et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology. 1992;49:295-304.
30. Hargreaves AC, Gunthorpe MJ, Taylor CW, Lummis SC. Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels. Mol Pharmacol. 1996;50: 1284-1294.
31. 3 receptor-mediated ion current in N1E-115 neuroblastoma cells by 5-hydroxyindole and analogues. Neuropharmacology. 1997;36:649-653.
32. 3-receptor functions by external H-7, a protein kinase inhibitor, in rat sensory neurones. Br J Pharmacol. 1997;122: 1195-1201.
33. Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer. 2002;10:139-145.
34. Eiselé J-L, Bertrand S, Galzi J-L, Devillers-Thiéry A, Changeux J-P, Bertrand D. Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities. Nature. 1993;366:479-483.
35. Steele JA, Martin IL. Interaction of oestrone and 17β-oestradiol with the 5-HT3 receptor. Br J Pharmacol. 1999;126:15P.
36. 3 receptor antagonists and emesis: a pre-clinical review. Pharm Med. 1995;13:153-191.
37. Davis MP, Homsi J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer. 2001;9:442-451.
38. Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol. 2002;20:2805-2811.
39. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999; 20:342-349.
40. 3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J. 2002;8:405-414.
41. Jann MW, Cohen LJ. The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression. Drug Metabol Drug Interact. 2000;16:39-67.
42. Aapro MS, Selak E, Lichinitser M, Santini D, Macciocchi A. Palonosetron (PALO) is more effective than ondansetron (OND) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC): results of a phase III trial [abstract 2918]. Proc Am Soc Clin Oncol. 2003;22:726.
43. 3 receptor antagonists the same? Eur J Cancer. 1992;28A(Suppl 1):S2-S6.
44. Riviere A, on behalf of The Granisetron Study Group. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer. 1994;69:967-971.
45. Kamanabrou D, on behalf of the Granisetron Study Group. Intravenous granisetron-establishing the optimal dose. Eur J Cancer. 1992;28A(Suppl 1):S6-S11.
46. Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol. 1994;12:2204-2210.
47. Minami M. Granisetron: is there a dose-response effect on nausea and vomiting? Cancer Chemother Pharmacol. 2003; 52:89-98.
48. Hacking A, on behalf of the Granisetron Study Group. Oral granisetron-simple and effective: a preliminary report. Eur J Cancer. 1992;28A(Suppl 1):S28-S32.
49. Bleiberg HH, Spielmann M, Falkson G, Romain D. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose ranging study. Clin Ther. 1995;17:38-51.
50. Soukop M, on behalf of the Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer. 1994;2:177-183.
51. Smith IE, on behalf of the Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. J Cancer Res Clin Oncol. 1993;119:350-354.
52. Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol. 1995;13:1242-1248.
53. Hesketh P, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol. 1996;14:2242-2249.
54. Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer. 1996;32A:807-813.
55. Grote TH, Pineda LF, Figlin RA, et al. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Cancer J Sci Am. 1997;3:45-51.
56. Bubalo J, Seelig F, Karbowicz S, Maziarz RT. Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:439-445.
57. Lindley C, Blower P. Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis. Am J Health Syst Pharm. 2000;57:1685-1697.
58. van Belle SJ, Stamatakis L, Bleiberg H, Cocquyt VF, Michel J, de Bruijn BCM. Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting. Ann Oncol. 1994;5:821-825.
59. Wymenga ANM, van der Graaf WTA, Wils JA, et al. A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy. Ann Oncol. 1996;7:505-510.
60. Mantovani G, Macciò A, Blanchi A, et al. Comparison of granisetron, ondansetron and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer. 1996;77:941-948.
61. Marty M, Kleisbauer J-P, Fournel P, et al. Is Navoban® (tropisetron) as effective as Zofran® (ondansetron) in cisplatin-induced emesis? Anti-Cancer Drugs. 1995;6(Suppl 1):15-21.
62. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol. 1995;6: 805-810.
63. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology. 1994;51:113-118.
64. Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992;10:1969-1975.
65. Tsavaris N, Kosmas M, Vadiaka A, et al. Efficacy of ondansetron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study. J Exp Clin Cancer Res. 2001;20:29-34.
66. Grunberg SM. Phase I and other dose-ranging studies of ondansetron. Semin Oncol. 1992;19(Suppl 10):16-22.
67. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy-a randomised study. Eur J Cancer. 1993;29A:1669-1672.
68. Seynaeve C, Schuller J, Buser K, et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Br J Cancer. 1992; 66:192-197.
69. Bosnjak SM, Neskovic-Konstantinovic ZB, Jovanovic-Micic DJ, Mitrovic LB, Radulovic SS. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. J Chemother. 1996; 8:315-318.
70. Dempsey CL, Coop AJ, Shillington A, Farley PA, Eberhardt DR, O'Briant S. Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide. Am J Health Syst Pharm. 2004; 61:781-786.
71. 3-receptor antagonists as prophylactic agents for acute chemotherapy-induced emesis [abstract A-29]. Support Care Cancer. 2003;11:394.
72. Needles B, Miranda E, Garcia Rodriguez FM, et al. A multi-center, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. Support Care Cancer. 1999;7: 347-353.
73. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol. 2004; 15:330-337.
74. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570-1577.
75. 3 receptor antagonist: results of a Phase III, single-dose trial versus dolasetron. Cancer. 2003; 98:2473-2482.
76. 3 receptors, in vitro. Br J Pharmacol. 1995;114:851-859.
77. de Wit R, de Boer AC, van der Linden GHM, Stoter G, Sparreboom A, Verweij J. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001;85:1099-1101.
78. Carmichael J, Keizer HJ, Cupissol D, Milliez J, Scheidel P, Schindler AE. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs. 1998;9:381-385.
79. Terrey J-P, Aapro MS, on behalf of the Granisetron Study Group. The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res. 1996;8:281-288.
80. 3 receptor blockade? Br J Cancer. 2002;86:1662-1663.
81. 1 antagonists; a new class of antiemetics. Br J Cancer. 2003;88:1823-1827.
82. 3 receptors. Neuropharmacology. 1993;32:729-735.
83. 3 antagonist. Eur J Cancer. 1990; 26(Suppl 1):S12-S15.
84. 3 receptor antagonist. Br J Clin Pharmacol. 1988;25:106P-107P.
85. Roche Laboratories. Kytril® (granisetron hydrochloride) [prescribing information]. Nutley: Roche Laboratories Inc., 2001.
86. GlaxoSmithKline. Zofran® (ondansetron hydrochloride) [prescribing information]. Research Triangle Park: GlaxoSmithKline, 2002.
87. Sweetland J, Lettis S, Fowler PA, Thomas M. Duration of the inhibitory effect of intravenous ondansetron on intradermal 5-HT-induced flare [abstract]. Br J Clin Pharmacol. 1992;33:565P.
88. Beck TM. The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron. Anticancer Drugs. 1995;6:237-242.
89. 4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Arch Pharmacol. 1993;347:137-140.
90. 3 receptor antagonist drugs. In: Dubois A, King GL, Livengood DR, editors. Radiation and the GI tract. Boca Raton: CRC Press Inc, 1995:37-49.
91. Elliott P, Seemungal BM, Wallis DI. Antagonism of the effects of 5-hydroxytryptamine on the rabbit isolated vagus nerve by BRL 43694 and metoclopramide. Naunyn Schmiedebergs Arch Pharmacol. 1990;341:503-509.
92. Hesketh PJ, Beck T, Uhlenhopp M, et al. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. J Clin Oncol. 1995;13:2117-2122.